Ovitrel

Ovitrelle refers to the pharmacological group of sex hormones and their synthetic analogues. The code of automatic telephone exchange G03GA08, the manufacturer - Merck Serono (Italy).

[1], [2]

Indications Ovitrel

Ovitrel is intended to treat infertility in women due to ovarian hypofunction or problems with natural ovulation. The drug is used for in vitro fertilization, and is also used to prepare the body for in vitro fertilization (IVF) - for the purpose of the final maturation of follicles after follicle-stimulating therapy.

Release form

Form release: lyophilized powder for the preparation of the injection solution in ampoules or in vials (complete with water for injection), the finished solution in syringes (0.25 and 0.5 ml). 

[3], [4]

Pharmacodynamics

Gonadotropic action Ovitrel - the initiation of ovulation - is provided by the recombinant hormone choriogonadotropin α, which is an analogue of endogenous human chorionic gonadotropin (hCG), synthesized by the placenta during pregnancy and having high luteinizing activity.

Linking to the receptors of luteinizing hormone (LH) on the cytoplasmic membranes of glycoproteins surrounding the ovarian follicles and basal membranes of the cell-cells, alpha-chorioradotropin induces the onset of the reduction division of the oocyte and ovulation (release of the oocyte from the follicle). In addition, from the granulosa cells of the follicle begins to form a yellow body of the ovary, which produces a large amount of progesterone.

[5], [6], [7], [8], [9]

Pharmacokinetics

After the administration of the drug under the skin, alpha-choriogonadotropin is absorbed into the extracellular fluid and enters the bloodstream, the bioavailability does not exceed 40%. The half-life of Ovitel is about 30 hours.

[10]

Dosing and administration

Ovitrel is used only in conditions of specialized medical institutions by physicians of the appropriate qualification.

Ovitrel is administered by subcutaneous injection (0.25 mg) according to a specific scheme that corresponds to the goal pursued. The use of this drug involves the preliminary administration of hormonal drugs based on menopausal gonadotropin or follicle-stimulating hormone.

[14], [15]

Use Ovitrel during pregnancy

Ovitrel during pregnancy is not used.

Contraindications

Ovitrel is contraindicated for:

• tumor formations of the pituitary or hypothalamus;
• hypertrophy and cystic ovarian disease;
• fibrotic hyperplasia in the uterus;
• malignant epithelial tumors (carcinomas) of the ovaries, uterus or mammary glands;
• uterine bleeding;
• cardiovascular pathologies (thrombosis, embolism).

[11], [12]

Side effects Ovitrel

The use of ovitrel may be accompanied by side effects such as headache, nausea, vomiting, diarrhea or constipation, decreased blood pressure, mastalgia (pain in the mammary glands), decreased urine production (oliguria), pain and a feeling of heaviness in the abdomen, thromboembolism, skin rashes , Quincke's edema, sleep and mood disorders.

[13]

Overdose

Ovitrel can lead to ovarian hyperstimulation - an increase in the size of the ovaries with the risk of their twisting and rupturing.

[16]

Interactions with other drugs

Ovitrel does not affect the effects of other drugs. According to the manufacturer, within a week after using this drug, a pregnancy test can be erroneously positive.

[17]

Storage conditions

In sealed packages, the drug should be stored at + 15-25 ° C; a bottle of powder in printed form - at a temperature of + 2-8 ° C for a maximum of 30 days; the drug in the unpacked syringe is not subject to storage.

Shelf life

Shelf life - 24 months.